Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

Introduction New HIV prevention strategies are urgently required. The discovery of broadly neutralising antibodies (bNAbs) has provided the opportunity to evaluate passive immunisation as a potential prevention strategy and facilitate vaccine development. Since 2014, several bNAbs have been isolated...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Nigel Garrett, Sharana Mahomed, Edmund Capparelli, Cheryl Baxter, Tanuja Gengiah, Derseree Archary, Penny Moore, Natasha Samsunder, Dan H Barouch, John Mascola, Julie Ledgerwood, Lynn Morris, Salim Abdool Karim, Catherine Hankins, Quarraisha A Karim, Nonhlanhla Y Zuma, Carolyn Williamson, Patricia E Fast, Bruno Pozzetto, Kevin Carlton, Nicole Doria-Rose
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2020-11-01
Serija:	BMJ Open
Online dostop:	https://bmjopen.bmj.com/content/10/11/e042247.full
Oznake:	Označite Brez oznak, prvi označite!